Nothing Special   »   [go: up one dir, main page]

DK0380230T3 - Immunogene sammensætninger mod gastrin-peptider - Google Patents

Immunogene sammensætninger mod gastrin-peptider

Info

Publication number
DK0380230T3
DK0380230T3 DK90300456.2T DK90300456T DK0380230T3 DK 0380230 T3 DK0380230 T3 DK 0380230T3 DK 90300456 T DK90300456 T DK 90300456T DK 0380230 T3 DK0380230 T3 DK 0380230T3
Authority
DK
Denmark
Prior art keywords
immunogenic compositions
disclosed
compositions against
compositions
treatment
Prior art date
Application number
DK90300456.2T
Other languages
English (en)
Inventor
Philip C Gevas
Stephen Grimes
Stephen L Karr Jr
Richard L Littenberg
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/301,353 external-priority patent/US5023077A/en
Application filed by Aphton Corp filed Critical Aphton Corp
Application granted granted Critical
Publication of DK0380230T3 publication Critical patent/DK0380230T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/595Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90300456.2T 1989-01-24 1990-01-17 Immunogene sammensætninger mod gastrin-peptider DK0380230T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,353 US5023077A (en) 1989-01-24 1989-01-24 Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US35119389A 1989-05-12 1989-05-12

Publications (1)

Publication Number Publication Date
DK0380230T3 true DK0380230T3 (da) 1995-01-16

Family

ID=26972322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90300456.2T DK0380230T3 (da) 1989-01-24 1990-01-17 Immunogene sammensætninger mod gastrin-peptider

Country Status (12)

Country Link
US (3) US5607676A (da)
EP (1) EP0380230B1 (da)
JP (1) JP2526418B2 (da)
AT (1) ATE114160T1 (da)
AU (1) AU645967B2 (da)
CA (1) CA2045594C (da)
DE (1) DE69014137T2 (da)
DK (1) DK0380230T3 (da)
ES (1) ES2063912T3 (da)
IE (1) IE66267B1 (da)
PT (1) PT92938B (da)
WO (1) WO1990008774A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US6861510B1 (en) * 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
DE69014137T2 (de) * 1989-01-24 1995-06-08 Aphton Corp., Woodland, Calif. Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
DE69740173D1 (de) * 1996-02-08 2011-05-26 Cancer Advances Inc Immunologische methoden zur behandlung von gastrointestinalem krebs
US6072086A (en) * 1996-04-12 2000-06-06 Intergen Company Method and composition for controlling formaldehyde fixation by delayed quenching
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
IL132546A0 (en) * 1997-04-23 2001-03-19 Univ Michigan Bradykinin analogs as selective inhibitors of cell activation
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
AU746754B2 (en) * 1997-05-12 2002-05-02 Cancer Advances, Inc. Immunogenic compositions to the CCK-B/gastrin-receptor and methods for the treatment of tumors
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
EP1579863A3 (en) * 1998-05-15 2008-03-19 Receptor Biologix, Inc. Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors
EP1077716B1 (en) * 1998-05-15 2005-07-27 Aphton Corporation Preparation of a medicament for the treatment of gastroesophageal reflux disease
EP1839673A3 (en) * 1998-05-15 2007-11-07 Receptor Biologix, Inc. Prevention and treatment of hypergastrinemia
JP2002515458A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 高ガストリン血症の予防および処置
KR100699574B1 (ko) * 1998-05-15 2007-03-23 리셉터 바이오로직스 인크 종양 치료를 위한 조합 치료
CA2331834A1 (en) * 1998-06-18 1999-12-23 Michal Y. Chowers Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
EP1372717A2 (en) * 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
DK1569680T3 (da) * 2002-10-22 2009-05-18 Waratah Pharmaceuticals Inc Behandling af diabetes
US20080096824A1 (en) * 2003-02-28 2008-04-24 Shigemi Matsuyama Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク. ガストリンホルモン免疫アッセイ
CN1997669A (zh) * 2004-03-29 2007-07-11 受体生物技术公司 抗胃泌素激素单克隆抗体
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
GB201121571D0 (en) * 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
AU2013289372B2 (en) 2012-07-13 2017-11-02 S-Target Therapeutics Gmbh Immunoregulatory vaccine
HUE037252T2 (hu) * 2013-05-21 2018-08-28 Tyg Oncology Ltd Gasztrin peptid immunogenikus kompozíció
AU2018283284B2 (en) 2017-06-15 2024-05-16 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932242A (en) * 1957-11-21 1976-01-13 Bartley Charles E Solid propellant with butyl rubber binder
DE2256445C3 (de) * 1972-11-17 1981-11-05 Hoechst Ag, 6000 Frankfurt Heptapeptide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
SU1414392A1 (ru) * 1982-12-29 1988-08-07 Всесоюзный кардиологический научный центр АМН СССР Противо звенное средство
FR2575164B1 (fr) * 1984-12-20 1987-03-20 Sanofi Sa Esters de tri- et tetrapeptides inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
DE69014137T2 (de) * 1989-01-24 1995-06-08 Aphton Corp., Woodland, Calif. Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17

Also Published As

Publication number Publication date
EP0380230A3 (en) 1991-06-26
US5607676A (en) 1997-03-04
DE69014137T2 (de) 1995-06-08
ATE114160T1 (de) 1994-12-15
EP0380230A2 (en) 1990-08-01
CA2045594A1 (en) 1990-07-25
JPH04503072A (ja) 1992-06-04
WO1990008774A1 (en) 1990-08-09
AU645967B2 (en) 1994-02-03
US5785970A (en) 1998-07-28
CA2045594C (en) 2002-08-13
ES2063912T3 (es) 1995-01-16
JP2526418B2 (ja) 1996-08-21
IE900250L (en) 1990-07-24
AU5082090A (en) 1990-08-24
US5609870A (en) 1997-03-11
DE69014137D1 (de) 1994-12-22
PT92938B (pt) 1996-09-30
EP0380230B1 (en) 1994-11-17
IE66267B1 (en) 1995-12-27
PT92938A (pt) 1990-07-31

Similar Documents

Publication Publication Date Title
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
DE3888273D1 (de) Medizinischer Apparat zur Behandlung mit Ultraschall.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
SE8703625D0 (sv) New medical use
DE69303803D1 (de) Behandlungsmethode zur Bodenverfestigung
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DK90888D0 (da) Maaleapparat til vaevsmetabolisme
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
ATE116550T1 (de) Behandlung von neoplastischen krankenheiten mit interleukin-10.
NO891823L (no) Overflatebehandling av haardt vev.
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DK67683D0 (da) Fremgangsmade til fremstilling af 2,3-diaryl-5-halogen-thio-phener
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69030584D1 (de) Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral
NO880292L (no) Fremgangsmaate for behandling av humle.
DE3873846D1 (de) Behandlungsapparat und verfahren.
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
BR9007738A (pt) Metodo de tratamento de couros
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.